Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

被引：0
|
作者：
Alireza Minagar
Irena Adamashvili
Roger E Kelley
Eduardo Gonzalez-Toledo
Jerry McLarty
Stacy J Smith
机构：
[1] LSU Health Sciences Center,Department of Neurology
[2] LSU Health Sciences Center,Department of Radiology
[3] LSU Health Sciences Center,Department of Internal Medicine
来源：
Journal of Neuroinflammation | / 4卷
关键词：
Multiple Sclerosis; Multiple Sclerosis Patient; Optic Neuritis; Natalizumab; RRMS Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The effect of interferon-β-1a on magnetisation transfer ratio in primary progressive multiple sclerosis
    Leary, SM
    Traboulsee, A
    Miller, DH
    Thompson, AJ
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S243 - S244
  • [32] Migration of T-cell subsets in multiple sclerosis and the effect of interferon-β1a
    Dressel, A.
    Mirowska-Guzel, D.
    Gerlach, C.
    Weber, F.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (03): : 164 - 168
  • [33] Safety and efficacy of combination therapy with interferon-β-1a and methotrexate in worsening multiple sclerosis
    Gharagozli, K
    Fallahi, F
    Mohammadi, MM
    Zadeh, MM
    Abdoli, N
    Abadian, S
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S263 - S263
  • [34] Ongoing efficacy and safety analysis of interferon-β1a (AVONEX) in patients with multiple sclerosis
    Herndon, RM
    Coats, M
    Goodkin, D
    Mass, M
    Richert, J
    Rudick, RA
    Weinstock-Guttman, B
    Simonian, NA
    Campion, M
    Scaramocci, J
    Alam, JJ
    Jacobs, LD
    ANNALS OF NEUROLOGY, 1997, 42 (06) : 987 - 987
  • [35] Differential immunomodulatory effects of interferon-β1a/1b in patients with multiple sclerosis
    Papachroni, K.
    Fragoulis, N.
    Piperi, C.
    Patrikiou, A.
    Papadimitriou, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 142 - 142
  • [36] Combined treatment of multiple sclerosis patients with cytostatics and interferon-β (1a,1b)
    Daskalovska, V
    Dimova, A
    Bojkovski, V
    Boskova-Petkovska, T
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S262 - S262
  • [37] The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
    Laurenske A. Visser
    Marc Folcher
    Claudia Delgado Simao
    Biotza Gutierrez Arechederra
    Encarna Escudero
    Carin A. Uyl-de Groot
    William Ken Redekop
    PharmacoEconomics, 2022, 40 : 91 - 108
  • [38] Subcutaneous interferon-β-1a in paediatric patients with multiple sclerosis: regional outcomes in an international retrospective study (REPLAY)
    Krupp, L. B.
    Pohl, D.
    Ghezzi, A.
    Boyko, A.
    Tenembaum, S.
    Meinel, M.
    Moraga, M. Stam
    McIlroy, C.
    Lehr, L.
    Banwell, B.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 298 - 298
  • [39] Safety of adult doses of subcutaneous interferon-β-1a in children and adolescents with multiple sclerosis: results of the REPLAY study
    Ghezzi, A.
    Pohl, D.
    Banwell, B.
    Krupp, L. B.
    Boyko, A.
    Meinel, M.
    Lehr, L.
    Moraga, M. Stam
    Tenembaum, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 74 - 75
  • [40] The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis
    Visser, Laurenske A.
    Folcher, Marc
    Delgado Simao, Claudia
    Gutierrez Arechederra, Biotza
    Escudero, Encarna
    Uyl-de Groot, Carin A.
    Redekop, William Ken
    PHARMACOECONOMICS, 2022, 40 (01) : 91 - 108
12345